7. Boston Scientific Corporation (NYSE:BSX)
Stock Upside: 60.39%
Market Capitalization: $69.52 billion
Boston Scientific Corporation (NYSE:BSX) ranks seventh on this list of the most promising healthcare stocks according to Wall Street analysts, and it is one of the largest and most institutionally followed names in the group. Trading at $45.29, with the stock up 0.76%, Boston Scientific Corporation (NYSE) has a market capitalization of $69.52 billion, a stock upside of 60.39%, and 106 hedge fund holders as of Q1 2026. For investors looking for medical device stocks, healthcare stocks with upside potential, large-cap healthcare stocks, cardiovascular device stocks, and Wall Street analyst stock picks, Boston Scientific remains a major player even as one of its most important cardiac products faces near-term questions.
On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE) from $85 to $64, while keeping a Buy rating on the stock. Analyst Richard Newitter cited a growing slowdown in demand for the company’s Watchman heart device. At first glance, a price-target cut may sound like bad news, but the Buy rating is important because it suggests Truist still sees upside despite lower expectations. That is often how Wall Street handles strong companies facing product-specific pressure. The firm may reduce its valuation assumptions while still believing the broader business remains attractive.
The Watchman device is central to this part of the Boston Scientific story. It is a small implant placed in the heart to help prevent blood clots from forming and traveling to the brain. The device is designed for patients with non-valvular atrial fibrillation, or AFib, and it serves as a one-time alternative to lifelong use of blood thinners. That matters because AFib is one of the most common heart rhythm disorders, and stroke prevention is a major priority for both patients and physicians. For years, Watchman has been one of Boston Scientific’s more visible growth franchises because it sits at the intersection of cardiology, minimally invasive treatment, and long-term stroke-risk management.
The recent concern, however, is procedure volume. According to Newitter, the issue began to build after Boston Scientific’s Q4 2025 results showed Watchman sales coming in about 1% below analyst expectations. The pressure became more visible when CEO Michael Mahoney spoke at Bernstein’s annual conference on May 27 and disclosed that physicians were increasingly combining Watchman procedures with other cardiac treatments in a single appointment instead of scheduling Watchman as a standalone procedure. That may sound like a small operational detail, but in medical devices, procedure patterns matter. If the same patient journey shifts from separate appointments to combined procedures, reported volumes and revenue timing can be affected.
Newitter interpreted this clinical-practice shift as a direct drag on Watchman procedure volumes. Mahoney also told investors to expect Watchman revenue to remain essentially flat from Q1 through Q2 and likely into Q3 2026 because of that shift. For short-term investors, that creates a clear issue. A slower Watchman growth path could weigh on sentiment around Boston Scientific, especially if investors had been counting on the device to keep delivering faster expansion. But for long-term investors, the broader Boston Scientific portfolio still matters. This is not a single-product biotech. It is a diversified medical device company with exposure to interventional cardiology, structural heart, electrophysiology, endoscopy, peripheral interventions, urology, and other medical specialties.
Boston Scientific Corporation (NYSE) develops, manufactures, and markets a broad portfolio of technologies used in interventional medicine. Its products include drug-eluting stents, structural heart therapies like the Watchman left atrial appendage closure device, and electrophysiology mapping and ablation systems. That product diversity is one reason the company continues to attract institutional attention. The presence of 106 hedge fund holders in Q1 2026 makes Boston Scientific one of the most widely held names on this list. For investors looking for healthcare value stocks, medical technology stocks, and large-cap healthcare stocks to buy, institutional interest can be an important signal, although it is never a guarantee of future returns.
The key question for Boston Scientific Corporation (NYSE) is whether Watchman’s near-term slowdown is a manageable pause or a sign of a more lasting issue. The market often punishes healthcare companies when a major product line slows, but the company’s size, product diversity, and analyst upside suggest that Wall Street still sees a bigger opportunity. With a 60.39% stock upside estimate and a $69.52 billion market capitalization, Boston Scientific remains a heavyweight medical device stock. It may not have the cleanest near-term story because of Watchman, but it still belongs in the conversation around the most promising healthcare stocks according to Wall Street analysts.
Click next to see the following stock...
